RAFA Rafarma Pharmaceuticals Video (translated)

New Post Public Reply Private Reply Replies (1) Message Board
equijohn
RAFA


Rafarma Pharmaceuticals Video (translated)

The history of the Rafarma company began in 2006. One of the largest projects in the Russian medical industry over the last several years, it was created by the health care services. The word Rafarma stands for Russian Antibiotics. The main activities of Rafarma are producing antibiotics, and conducting scientific research in the area of new antibiotic development. The manufacturing facility is being built in Lipetskaya oblast in the special economic zone called Terbuny.

Aleksand Vasilievich, President & CEO of Rafarma

“In 2009 Vnesheconom Bank provided a 66 million euro loan, to be paid back over 7 years, for the construction of the facility”.

This decision was made at the highest levels, where Putin was the chairman of Vnesheconom Bank . The construction is also supported by Russia's Ministry of Industry and Trade and by the Ministry of Health and Social Development, in addition to support from the administration of the Lipetskiy region. This project reflects the strategy of the Russian Federation for the pharmaceutical industry, which was developed for the period until 2020. The high point of this project is to establish a modern, highly-efficient production base which would satisfy GMP standards, making Rafarma products highly competitive in domestic and global markets. The Rafarma plant is being built in two stages. The first stage concludes at the end of 2010 or the beginning of 2011. The entire plant will go online in the beginning of 2012.

Aleksand Vasilievich, President & CEO of Rafarma

“The production includes both widely-known antibiotics as well as more specific types, such as cytostatic drugs.

Rafarma's goal is to become the largest pharmaceutical plant in Russia, satisfying both GMP and world standards, and to create favorable conditions to attract the largest pharmaceutical companies from outside Russia engage in contract-based pharmaceutical production.

Aleksand Evgenievich Polstyanov, Development Director of Rafarma

“Because antibiotics are special with respect to drug production and require specific technology for manufacturing, according to GMP standards their production should be separated from the production of other kinds of drugs. The idea behind this project is to create a facility where each building segment will be responsible for the production of certain types of drug. For example, for penicillin production there will be a building block where all drugs that include penicillin will be produced, including injection types represented by dry powder, dry suspended mixtures for children, and oral forms like capsules and pills. The second building block will be engaged in cephalosporin production. Although both penicillin and cephalosporin belong to beta-lactam antibiotics, they require separate manufacturing facilities. The third building block will produce non-beta-lactam antibiotics which include macrolides and fluoruquinolones in various forms such as injections and oral forms. The plant will also be capable to produce cytostatic drugs which are also called anti-oncological drugs. They will be produced in a separate building block where there will be no contact with other drugs or people.”


All production departments will share one packaging and storage area where packaging, labeling, and other activities that don't invlove interaction with the active drug ingredients will be performed. Such alignment will satisfy the world-standards requirements in pharmaceutical production. Production of 101 million units of antibiotics and 869 thousand units of antitumorals per year will cover six main consumer segments: Moscow and the Moscow region, the Krasnodar region, Saint-Petersburg, and the republics of Bashkortostan and Tatarstan.
Rafarma manufactures 28 antibiotic products and 11 cytostatic products. Rafarma production will cover 20% of sales in Russia, bringing the importation of foreign drugs down by 60-70 %.

Aleksand Evgenievich Polstyanov, Development Director of Rafarma

“The facility will also be capable of assisting pharmaceutical production in general. For example, it will produce glass for pharmaceutical needs, ampules, and mattresses(vials), as well as packaging materials. It will also perform distribution functions, covering several areas in the Central Federal region.”

The plant is built in such a manner so that in the future it can expand even more. The plant itself is the first stage in creating a pharmaceutical base in the Lipetskiy region. The Health project has plans to build four pharmaceutical plants.

Aleksand Evgenievich Polstyanov, Development Director of Rafarma

“Rafarms is the first fruit, the engineering and beginning of construction performed by a foreign company, Jim Project. Our general contractor is another Czech company Unistaf.”

Today, Rafarma works on several innovative projects. This is possible due to collaboration with several leading scientific establishments.

Alexey Mihailovich Egorov, Vice Director of Scientific Development

The main area of our research is the creation of new technologies. Our country used to be a leader in pharmaceutical production in the Soviet era, but lost this position, so we are working on creating new methods by using innovative methods of bioengineering.”

In 2007 a Chernogolovka branch was opened.

Pavel Yurievich, CEO of Rafarma's branch in Chernogolovka

“Nowadays this complex comprises more than 1000 square meters within which we can conduct research on creating new medical products, starting with creating the basic chemical molecule of a new active ingredient, up to the production of a new medical formula.”

Now Rafarma can produce all kinds of medical products that satisfy GMP requirements.

Pavel Yurievich, CEO of Rafarma's branch in Chernogolovka

“We have a sector that manufactures medical substances in volumes of 2,6, 10, 50, and 100 liters.”

All research work is conducted under Russian Academy of Science.

Pavel Yurievich, CEO of Rafarma's branch in Chernogolovka

“Doctors and masters of sciences work in our facility. Here we have both production labs and labs designated for research work, where we can test the manufactured products and work on creating new ones.”

Rafarma produces a new form of medical product which has prolonged features, allowing a pill to be taken just once in several days. Prolonged formulas decrease the amount of intake of the product, thereby decreasing its side effects.

Alexey Mihailovich Egorov, Vice Director of Scientific Development

“An example of such a prolonged product is risperidone. It allows for a consumption rate 100 times less than normal. It is much safer for the patient. This can also be said about antibiotics. For example, azithromycin can be produced in micro granules. One dose of two grams over ten days period can cure from various respiratory system diseases.”

One of the biggest problems in modern medicine is the development of drug resistance. Over the last fifty years bacteria have learned how to produce more than fifty types of different ferments that destroy antibiotics. The task ahead for the modern pharmaceutical world is to learn how to produce antibiotics that will be effective and resistance-efficient.

Alexey Mihailovich Egorov, Vice Director of Scientific Development

“Rafarma creates a product with a fluorine molecule that destroys a cell's membrane . It can work both internally and externally, when emergent care is required.”

Another task for modern medicine is to diagnose diseases as fast and early as possible.

Alexey Mihailovich Egorov, Vice Director of Scientific Development

“Along with Moscow University we are working on creating biochips which allow the identification of several hundred parameters of causative organism and their mechanisms of resistance. Now we can perform the diagnosis within several hours instead of several days, like it used to be.”

Rafarma works closely with Moscow State University, the Russian Academy of Science, the Insitute of Chemical Physics in Chernogolovka, the Institute of Laser Technology, and RUDN University.

Alexey Mihailovich Egorov, Vice Director of Scientific Development

“Scientists who work with us create a very strong, although virtual, workforce. I'm confident that after the construction is done, we will be able to organize the production of highly-efficient and competitive products”.

The realization of Rafarma project will promote the overall health of the population and increase lifespans, due to the increased safety of medical products and the decreased reliance on foreign imports.

EJstocks.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 181

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 118

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 102

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 372

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenCore Solutions Unveils Innovative Partnership for Eco-Friendly Diapers

Updated Category News Views 165

New Collaboration to Enhance Retail Visibility GreenCore Solutions Corp., a frontrunner in eco-friendly diaper innovation, has joined forces with Emerson TEN OÜ. This strategic partnership aims to elevate the visibility of GreenCore's TreeFree Diaper products across European retail settings, including grocery and convenience stores. Transforming the Shopping Experience...

Continue Reading
Oman's Stock Exchange Sees Unprecedented Growth to $8.45 Billion

Updated Category News Views 339

Oman's Muscat Stock Exchange Achieves Significant Trading Growth Recent reports indicate that Oman's Muscat Stock Exchange (MSX) has experienced a remarkable performance, marking the highest trading values seen in many years. Fueled by reforms initiated by the Oman Investment Authority (OIA), the exchange has recorded an impressive trading value of approximately USD 8.45...

Continue Reading
Gloo Partners with Servant to Transform Faith-Based Organizations

Updated Category News Views 409

Gloo's Strategic Investment in Servant In an exciting new development for the faith ecosystem, Gloo has announced a significant investment in Servant, a leading consultancy dedicated to assisting organizations in their growth and digital transformation efforts. This partnership highlights Gloo's commitment to enhancing the capabilities of various faith-based...

Continue Reading
Movate Enhances AI Solutions by Acquiring Prescience for Growth

Updated Category News Views 332

Acquisition Announcement by Movate Movate, a prominent provider of digital technology services, has made a strategic move by acquiring Prescience, a key player in the field of data science and artificial intelligence. This acquisition marks a significant step for Movate as it aims to embed AI deeply into its service offerings. Through this merger, Movate seeks to enable...

Continue Reading
Stellantis Faces Rising Tensions as UAW Considers Strikes Ahead

Updated Category News Views 88

Tensions Rise Between Stellantis and UAW Stellantis, the French-Italian automotive powerhouse, is facing growing scrutiny as the United Auto Workers (UAW) union gears up for potential strikes due to allegations of contract violations. This situation emerges almost a year after a major national walkout, which led to significant losses for the Detroit Three automakers and...

Continue Reading